GenSight Biologics annonce la publication des résultats cliniques à cinq ans pour les patients traités unilatéralement avec la thérapie génique LUMEVOQ®

Long-term Efficacy of LUMEVOQ®: GenSight Biologics announced five-year follow-up data showing that patients treated with LUMEVOQ®, a gene therapy for Leber's hereditary optic neuropathy (LHON), experienced sustained improvements in visual acuity and safety, with 66.1% achieving clinically significant vision improvement.

Study Details and Patient Outcomes: The RESTORE study, involving 62 participants, demonstrated that the majority maintained or improved their vision after treatment, and quality of life scores significantly increased over the five-year period, indicating the therapy's potential benefits for patients with LHON caused by the ND4 mutation.